Compare Entegris Inc (ENTG) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Entegris Inc trades at $145.48 (market cap $24.63B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Entegris Inc is far larger — about 25.3× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Entegris Inc pays a 0.25% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Entegris Inc for 41 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| ENTG | MRVI | |
|---|---|---|
Market Cap | $24.63B | $972.90M |
Volume | 2,062,440 | 4,325,710 |
Sector | Technology | Health |
52-Week High | $184.00 | $9.00 |
52-Week Low | $68.80 | $2.83 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | $27.83B | $1.08B |
Dividend Yield | 0.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Entegris (ENTG) trades at $153.08, down 4.33% amid broader market weakness, yet maintains strong analyst support with a $186.56 consensus price target. The semiconductor materials company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.93 surpassing expectations by 13%. Technical indicators show a bullish moving average trend while fundamentals reveal elevated valuation metrics (P/E 80.58) offset by robust profitability (9.18% net margin) and positive cash flow generation.
Investment outlook remains favorable given Entegris's positioning in high-growth semiconductor segments and AI-driven demand, though valuation concerns and debt levels warrant monitoring. The stock offers 22% upside to consensus targets but faces execution risks in a cyclical industry. Recent institutional accumulation and patent defense successes provide additional confidence in the company's competitive moat.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
